Project ALS and Amylyx Enter Collaboration to Test AMX0035

Home
news
Project ALS and Amylyx Enter Collaboration to Test AMX0035

Project ALS and Amylyx Enter Collaboration to Test AMX0035

Amylyx closes a $ 5 million Series A Investment

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Recent Posts

Prilenia enrolls first ALS patient in their Phase II / III study
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board